T-Cell Lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "T-Cell Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in T-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the T-Cell Lymphoma Pipeline Report

* DelveInsight's T-Cell Lymphoma pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for T-Cell Lymphoma treatment.
* The leading T-Cell Lymphoma Companies working in the market include Soligenix, CStone Pharmaceuticals, Genor Biopharma, Innate Pharma, ImmuneOncia Therapeutics, Astex Pharmaceuticals, Corvus Pharmaceuticals, ViGenCell Inc., Affimed GmbH, MediSix Therapeutics, Dialectic Therapeutics, Artiva Biotherapeutics Inc. and others.
* Promising T-Cell lymphoma pipeline therapies in the various stages of development include Brentuximab Vedotin, Sorafenib, chidamide, cyclophosphamide, liposomal doxorubicin, and others.
* May 2024:- SciTech Development, LLC- A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion. The product formulation in the current study (ST-001) is a phospholipid suspension of nanoparticle sized fenretinide. The current study is a Phase 1 trial in relapsed/refractory (R/R) T-cell non-Hodgkin's lymphoma in order to determine the safety profile, pharmacology, and maximum tolerated dose (MTD) of ST-001 nanoFenretinide.
* April 2024:- Bristol-Myers Squibb- A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan. The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 in participants with relapsed or refractory T-cell lymphomas in Japan.

Request a sample and discover the recent advances in T-Cell Lymphoma @ T-Cell Lymphoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

T-Cell Lymphoma Overview

T-cell lymphomas are the uncommon and rare subtype of non-Hodgkin lymphomas that can develop in lymphoid tissues such as the lymph nodes and spleen, or outside of lymphoid tissues (i.e., gastrointestinal tract, liver, nasal cavity, skin, and others). This disease group has a poor prognosis compared to their B-cell counterpart. Most T-cell lymphomas develop from mature T cells. They usually affect adults, typically in people in their mid-60s.

The type of treatment needed for T-cell lymphoma will depend on the subtype of lymphoma, whether it is indolent or aggressive, symptoms and personal preferences. Some common treatment options include chemotherapy, monoclonal antibodies (Mabs) including cytokine inhibitors and conjugated Mabs, targeted therapies, and radiotherapy.

T-Cell Lymphoma Emerging Drugs

* SGX 301: Soligenix

SGX301 (HyBryte Trademark / synthetic hypericin) is a novel, first-in-class photodynamic therapy utilizing safe visible light for activation. SGX301 is a photodynamic topical therapy using a hypericin ointment activated by visible light which is intended for patients managing early stage CTCL disease progression. HyBryte Trademark has been granted both Orphan Drug and Fast Track designation in the US, Orphan Drug designation in Europe and Promising Innovative Medicine designation by the UK Health Authority. The company has submitted a new drug application (NDA) to the US FDA)for HyBryte Trademark (synthetic hypericin) in the treatment of early stage cutaneous T-cell lymphoma (CTCL).

* Sugemalimab: CStone Pharmaceuticals

Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. As a fully human, full-length anti-PD-L1 monoclonal antibody, sugemalimab mirrors the natural G-type immunoglobulin 4 (IgG4) human antibody, which reduces the risk of immunogenicity and potential toxicities in patients, a unique advantage over similar drugs. In September 2022, the National Medical Products Administration (NMPA) of China has accepted and granted priority review to the supplemental new drug application (sNDA) for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL).

* IMC-001: ImmuneOncia Therapeutics

IMC-001 (STI-3031) is a fully human anti-PD-L1 IgG1 type monoclonal antibody that has shown promising results in terms of safety and efficacy in the dose-escalation first-in-human study although the patients were heavily pretreated. IgG1 type antibody targeting PD-L1 on tumor enables unique combinations, such as with an NK cell-based therapy, unique in its property among other PD-1/PD-L1 targeting agents. The drug is in Phase II for the treatment of NK/T-cell lymphoma.

* Tolinapant: Astex Pharmaceuticals

Tolinapant (ASTX660) is a potent, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Tolinapant has a unique IAP antagonist molecular profile and has been shown to exert its activity through both IAP antagonism and via an immune-related mechanism. Currently, the drug is being evaluated in the Phase I/II (NCT05403450) for patients with peripheral T-cell lymphoma.

* CPI-818: Corvus Pharmaceuticals

CPI-818 is an oral, small molecular drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase) and has the potential to provide a platform opportunity with broad applicability across lymphomas, solid tumors and autoimmune/allergic diseases. The optimal dose of CPI-818 has the potential to induce the activation, differentiation and expansion of T cells to TH1 helper cells while blocking the deployment of TH2 cells (TH1 skewing). Corvus and its partner in China, Angel Pharmaceuticals are conducting a Phase I trial in patients with refractory T-cell lymphomas that was designed to select the optimal dose of CPI-818 and evaluate its safety, pharmacokinetics, target occupancy, immunologic effects, biomarkers and efficacy.

Learn more about T-Cell Lymphoma in clinical trials @ T-Cell Lymphoma Drugs [https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

T-Cell Lymphoma Therapeutics Assessment

There are approx. 90+ key companies which are developing the therapies for T-cell Lymphoma. The T-Cell Lymphoma companies which have their T-cell Lymphoma drug candidates in the most advanced stage, i.e. registered include, CStone Pharmaceuticals.

DelveInsight's T-Cell Lymphoma pipeline report covers around 90+ products under different phases of clinical development like

* Late stage products (Registered)
* Late stage products (Pre-registration)
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Discover more about T-Cell Lymphoma in development @ T-Cell Lymphoma Clinical Trials [https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

T-Cell Lymphoma Companies

Soligenix, CStone Pharmaceuticals, Genor Biopharma, Innate Pharma, ImmuneOncia Therapeutics, Astex Pharmaceuticals, Corvus Pharmaceuticals, ViGenCell Inc., Affimed GmbH, MediSix Therapeutics, Dialectic Therapeutics, Artiva Biotherapeutics Inc. and others.

T-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

T-Cell Lymphoma Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

To know more about T-Cell Lymphoma, visit @ T-Cell Lymphoma Segmentation [https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the T-Cell Lymphoma Pipeline Report

* Coverage- Global
* T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* T-Cell Lymphoma Companies- Soligenix, CStone Pharmaceuticals, Genor Biopharma, Innate Pharma, ImmuneOncia Therapeutics, Astex Pharmaceuticals, Corvus Pharmaceuticals, ViGenCell Inc., Affimed GmbH, MediSix Therapeutics, Dialectic Therapeutics, Artiva Biotherapeutics Inc. and others.
* T-Cell lymphoma pipeline therapies- Brentuximab Vedotin, Sorafenib, chidamide, cyclophosphamide, liposomal doxorubicin, and others.

For further information on the T-Cell Lymphoma Pipeline Therapeutics, reach out @ T-Cell Lymphoma Products Development [https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* T-cell Lymphoma : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* T-cell Lymphoma - DelveInsight's Analytical Perspective
* Late Stage Products (Pre-registration)
* SGX 301: Soligenix
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IMC-001: ImmuneOncia Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Tolinapant: Astex Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* T-cell Lymphoma Key Companies
* T-cell Lymphoma Key Products
* T-cell Lymphoma Unmet Needs
* T-cell Lymphoma Market Drivers and Barriers
* T-cell Lymphoma Future Perspectives and Conclusion
* T-cell Lymphoma Analyst Views
* T-cell Lymphoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=tcell-lymphoma-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.